Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program.
Publication
, Journal Article
Houghton, PJ; Kang, MH; Reynolds, CP; Morton, CL; Kolb, EA; Gorlick, R; Keir, ST; Carol, H; Lock, R; Maris, JM; Billups, CA; Smith, MA
Published in: Pediatr Blood Cancer
April 2012
LCL161, a SMAC mimetic, was tested against the PPTP in vitro panel (1.0 nM to 10.0 µM) and the PPTP in vivo panels (30 or 75 mg/kg [solid tumors] or 100 mg/kg [ALL]) administered orally twice in a week. LCL161 showed a median relative IC(50) value of >10 µM, being more potent against several leukemia and lymphoma lines. In vivo LCL161 induced significant differences in EFS distribution in approximately one-third of solid tumor xenografts (osteosarcoma and glioblastoma), but not in ALL xenografts. No objective tumor responses were observed. In vivo LCL161 demonstrated limited single agent activity against the pediatric preclinical models studied.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Pediatr Blood Cancer
DOI
EISSN
1545-5017
Publication Date
April 2012
Volume
58
Issue
4
Start / End Page
636 / 639
Location
United States
Related Subject Headings
- Xenograft Model Antitumor Assays
- Transplantation, Heterologous
- Peptidomimetics
- Oncology & Carcinogenesis
- Oligopeptides
- Neoplasms
- Neoplasm Transplantation
- Mice, Nude
- Mice
- Humans
Citation
APA
Chicago
ICMJE
MLA
NLM
Houghton, P. J., Kang, M. H., Reynolds, C. P., Morton, C. L., Kolb, E. A., Gorlick, R., … Smith, M. A. (2012). Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer, 58(4), 636–639. https://doi.org/10.1002/pbc.23167
Houghton, Peter J., Min H. Kang, C Patrick Reynolds, Christopher L. Morton, E Anders Kolb, Richard Gorlick, Stephen T. Keir, et al. “Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program.” Pediatr Blood Cancer 58, no. 4 (April 2012): 636–39. https://doi.org/10.1002/pbc.23167.
Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R, et al. Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2012 Apr;58(4):636–9.
Houghton, Peter J., et al. “Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program.” Pediatr Blood Cancer, vol. 58, no. 4, Apr. 2012, pp. 636–39. Pubmed, doi:10.1002/pbc.23167.
Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Billups CA, Smith MA. Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2012 Apr;58(4):636–639.
Published In
Pediatr Blood Cancer
DOI
EISSN
1545-5017
Publication Date
April 2012
Volume
58
Issue
4
Start / End Page
636 / 639
Location
United States
Related Subject Headings
- Xenograft Model Antitumor Assays
- Transplantation, Heterologous
- Peptidomimetics
- Oncology & Carcinogenesis
- Oligopeptides
- Neoplasms
- Neoplasm Transplantation
- Mice, Nude
- Mice
- Humans